Tatiana M Astakhova, Nikita S Karpov, Nataliya O Dashenkova, Elena V Alpeeva, Mikhail V Nesterchuk, Sergey B Akopov, Arsen S Mikaelyan, Anfisa S Ryabchenko, Pavel A Erokhov, Natalia P Sharova
{"title":"抑制LMP2蛋白酶体活性抑制小鼠结肠腺癌组织中Chil3的表达并抑制肿瘤生长。","authors":"Tatiana M Astakhova, Nikita S Karpov, Nataliya O Dashenkova, Elena V Alpeeva, Mikhail V Nesterchuk, Sergey B Akopov, Arsen S Mikaelyan, Anfisa S Ryabchenko, Pavel A Erokhov, Natalia P Sharova","doi":"10.32604/or.2025.066611","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Proteasomes, multi-subunit proteases, are key actors of cellular protein catabolism and a number of regulatory processes. The detection of subtle proteasome functioning in tumors may contribute to our understanding of the mechanisms of cancer development. The current study aimed to identify the role of low molecular mass protein 2 (LMP2), a proteasome immune subunit, in the development of mouse colon 26 (C26) adenocarcinoma.</p><p><strong>Methods: </strong>The functions of the LMP2 subunit in tumor development in Balb/c mice were studied using its irreversible inhibitor KZR-504. LMP2 activity was detected by the hydrolysis of the fluorogenic substrate Ac-Pro-Ala-Leu-AMC. Western blotting and Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) were used. We applied fluorescent tests for cell proliferation and apoptosis. M2 macrophages were obtained by polarization of mouse bone marrow-derived macrophages using the corresponding cytokines.</p><p><strong>Results: </strong>KZR-504 showed high specificity only for the LMP2 subunit and had no negative effect on C26 cells in culture. However, KZR-504 suppressed the formation of tumor conglomerates (by 74%, <i>p</i> < 0.001) after C26 cell transplantation <i>in vivo</i>, inhibited the expression of chitinase-3-like protein 3 (Chil3) gene (by 90%, <i>p</i> < 0.001), a key marker of immunosuppressive M2 macrophages, in the tumor microenvironment, and reduced the tumor weight compared to the control (by 48%, <i>p</i> < 0.01). KZR-504 also suppressed the expression of <i>Chil3</i> (by 68%, <i>p</i> < 0.05) and arginase-1 (Arg1) (by 90%, <i>p</i> < 0.001), another marker gene, in M2 macrophages and violated M0-M2 macrophage polarization in culture.</p><p><strong>Conclusion: </strong>We discovered earlier unknown functions of the proteasome LMP2 subunit to facilitate the formation of tumor conglomerates and maintain <i>Chil3</i> and <i>Arg1</i> expression in immunosuppressive M2 macrophages. Our work demonstrates that the proteasome LMP2 subunit can be a target for antitumor treatment.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 9","pages":"2573-2595"},"PeriodicalIF":4.1000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408852/pdf/","citationCount":"0","resultStr":"{\"title\":\"Inhibition of Proteasome LMP2 Activity Suppresses <i>Chil3</i> Expression in Mouse Colon Adenocarcinoma Tissue and Restrains Tumor Growth.\",\"authors\":\"Tatiana M Astakhova, Nikita S Karpov, Nataliya O Dashenkova, Elena V Alpeeva, Mikhail V Nesterchuk, Sergey B Akopov, Arsen S Mikaelyan, Anfisa S Ryabchenko, Pavel A Erokhov, Natalia P Sharova\",\"doi\":\"10.32604/or.2025.066611\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Proteasomes, multi-subunit proteases, are key actors of cellular protein catabolism and a number of regulatory processes. The detection of subtle proteasome functioning in tumors may contribute to our understanding of the mechanisms of cancer development. The current study aimed to identify the role of low molecular mass protein 2 (LMP2), a proteasome immune subunit, in the development of mouse colon 26 (C26) adenocarcinoma.</p><p><strong>Methods: </strong>The functions of the LMP2 subunit in tumor development in Balb/c mice were studied using its irreversible inhibitor KZR-504. LMP2 activity was detected by the hydrolysis of the fluorogenic substrate Ac-Pro-Ala-Leu-AMC. Western blotting and Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) were used. We applied fluorescent tests for cell proliferation and apoptosis. M2 macrophages were obtained by polarization of mouse bone marrow-derived macrophages using the corresponding cytokines.</p><p><strong>Results: </strong>KZR-504 showed high specificity only for the LMP2 subunit and had no negative effect on C26 cells in culture. However, KZR-504 suppressed the formation of tumor conglomerates (by 74%, <i>p</i> < 0.001) after C26 cell transplantation <i>in vivo</i>, inhibited the expression of chitinase-3-like protein 3 (Chil3) gene (by 90%, <i>p</i> < 0.001), a key marker of immunosuppressive M2 macrophages, in the tumor microenvironment, and reduced the tumor weight compared to the control (by 48%, <i>p</i> < 0.01). KZR-504 also suppressed the expression of <i>Chil3</i> (by 68%, <i>p</i> < 0.05) and arginase-1 (Arg1) (by 90%, <i>p</i> < 0.001), another marker gene, in M2 macrophages and violated M0-M2 macrophage polarization in culture.</p><p><strong>Conclusion: </strong>We discovered earlier unknown functions of the proteasome LMP2 subunit to facilitate the formation of tumor conglomerates and maintain <i>Chil3</i> and <i>Arg1</i> expression in immunosuppressive M2 macrophages. Our work demonstrates that the proteasome LMP2 subunit can be a target for antitumor treatment.</p>\",\"PeriodicalId\":19537,\"journal\":{\"name\":\"Oncology Research\",\"volume\":\"33 9\",\"pages\":\"2573-2595\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408852/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.32604/or.2025.066611\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2025.066611","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:蛋白酶体,多亚基蛋白酶,是细胞蛋白质分解代谢和许多调节过程的关键参与者。检测肿瘤中细微的蛋白酶体功能可能有助于我们对癌症发展机制的理解。目前的研究旨在确定低分子质量蛋白2 (LMP2),一种蛋白酶体免疫亚基,在小鼠结肠26 (C26)腺癌发展中的作用。方法:利用LMP2不可逆抑制剂KZR-504研究LMP2亚基在Balb/c小鼠肿瘤发生中的作用。通过水解荧光底物Ac-Pro-Ala-Leu-AMC来检测LMP2的活性。采用免疫印迹法和定量反转录聚合酶链反应(qRT-PCR)。应用荧光法检测细胞增殖和凋亡。利用相应的细胞因子对小鼠骨髓源性巨噬细胞进行极化,获得M2巨噬细胞。结果:KZR-504仅对LMP2亚基具有高特异性,对培养的C26细胞无不良影响。而KZR-504在体内可抑制C26细胞移植后肿瘤团簇的形成(74%,p < 0.001),抑制肿瘤微环境中免疫抑制M2巨噬细胞关键标志物几丁质酶-3样蛋白3 (Chil3)基因的表达(90%,p < 0.001),使肿瘤重量较对照组减轻(48%,p < 0.01)。KZR-504还抑制了M2巨噬细胞中另一标记基因Chil3 (68%, p < 0.05)和arginase-1 (Arg1) (90%, p < 0.001)的表达,并在培养中破坏了M0-M2巨噬细胞的极化。结论:我们发现了早期未知的蛋白酶体LMP2亚基在免疫抑制的M2巨噬细胞中促进肿瘤聚集形成和维持Chil3和Arg1表达的功能。我们的工作表明,蛋白酶体LMP2亚基可以成为抗肿瘤治疗的靶标。
Inhibition of Proteasome LMP2 Activity Suppresses Chil3 Expression in Mouse Colon Adenocarcinoma Tissue and Restrains Tumor Growth.
Objectives: Proteasomes, multi-subunit proteases, are key actors of cellular protein catabolism and a number of regulatory processes. The detection of subtle proteasome functioning in tumors may contribute to our understanding of the mechanisms of cancer development. The current study aimed to identify the role of low molecular mass protein 2 (LMP2), a proteasome immune subunit, in the development of mouse colon 26 (C26) adenocarcinoma.
Methods: The functions of the LMP2 subunit in tumor development in Balb/c mice were studied using its irreversible inhibitor KZR-504. LMP2 activity was detected by the hydrolysis of the fluorogenic substrate Ac-Pro-Ala-Leu-AMC. Western blotting and Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) were used. We applied fluorescent tests for cell proliferation and apoptosis. M2 macrophages were obtained by polarization of mouse bone marrow-derived macrophages using the corresponding cytokines.
Results: KZR-504 showed high specificity only for the LMP2 subunit and had no negative effect on C26 cells in culture. However, KZR-504 suppressed the formation of tumor conglomerates (by 74%, p < 0.001) after C26 cell transplantation in vivo, inhibited the expression of chitinase-3-like protein 3 (Chil3) gene (by 90%, p < 0.001), a key marker of immunosuppressive M2 macrophages, in the tumor microenvironment, and reduced the tumor weight compared to the control (by 48%, p < 0.01). KZR-504 also suppressed the expression of Chil3 (by 68%, p < 0.05) and arginase-1 (Arg1) (by 90%, p < 0.001), another marker gene, in M2 macrophages and violated M0-M2 macrophage polarization in culture.
Conclusion: We discovered earlier unknown functions of the proteasome LMP2 subunit to facilitate the formation of tumor conglomerates and maintain Chil3 and Arg1 expression in immunosuppressive M2 macrophages. Our work demonstrates that the proteasome LMP2 subunit can be a target for antitumor treatment.
期刊介绍:
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.